Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines
Precision medicines can benefit patients by increasing the probability of a successful treatment response in selected patient populations. The potential for more immediate signals of efficacy during clinical trials suggests such medicines will reach the market more rapidly than traditional drugs will. Using data from the Food and Drug Administration (FDA), we examined the regulatory review and pivotal trial characteristics of precision medicines. We found that in the period January 2013-June 2017, precision medicines were developed and reviewed almost two years faster than nonprecision medicines. In addition, approximately 48 percent of the precision medicines in our study qualified for the FDA's breakthrough therapy designation. Precision medicines were also approved based on fewer pivotal trials with fewer patients, and the trials were less likely to be randomized, blinded, or controlled with either an active or placebo comparator.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Health affairs (Project Hope) - 37(2018), 5 vom: 01. Mai, Seite 724-731 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pregelj, Lisette [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological Products |
|---|
| Anmerkungen: |
Date Completed 21.01.2019 Date Revised 21.01.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1377/hlthaff.2017.1580 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM283807741 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM283807741 | ||
| 003 | DE-627 | ||
| 005 | 20231225041745.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1377/hlthaff.2017.1580 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0946.xml |
| 035 | |a (DE-627)NLM283807741 | ||
| 035 | |a (NLM)29733717 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pregelj, Lisette |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.01.2019 | ||
| 500 | |a Date Revised 21.01.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Precision medicines can benefit patients by increasing the probability of a successful treatment response in selected patient populations. The potential for more immediate signals of efficacy during clinical trials suggests such medicines will reach the market more rapidly than traditional drugs will. Using data from the Food and Drug Administration (FDA), we examined the regulatory review and pivotal trial characteristics of precision medicines. We found that in the period January 2013-June 2017, precision medicines were developed and reviewed almost two years faster than nonprecision medicines. In addition, approximately 48 percent of the precision medicines in our study qualified for the FDA's breakthrough therapy designation. Precision medicines were also approved based on fewer pivotal trials with fewer patients, and the trials were less likely to be randomized, blinded, or controlled with either an active or placebo comparator | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Designations | |
| 650 | 4 | |a Precision medicines | |
| 650 | 4 | |a Speed | |
| 650 | 4 | |a Trial size | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Hwang, Thomas J |e verfasserin |4 aut | |
| 700 | 1 | |a Hine, Damian C |e verfasserin |4 aut | |
| 700 | 1 | |a Siegel, Evan B |e verfasserin |4 aut | |
| 700 | 1 | |a Barnard, Ross T |e verfasserin |4 aut | |
| 700 | 1 | |a Darrow, Jonathan J |e verfasserin |4 aut | |
| 700 | 1 | |a Kesselheim, Aaron S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Health affairs (Project Hope) |d 1981 |g 37(2018), 5 vom: 01. Mai, Seite 724-731 |w (DE-627)NLM012834297 |x 1544-5208 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2018 |g number:5 |g day:01 |g month:05 |g pages:724-731 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1377/hlthaff.2017.1580 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2018 |e 5 |b 01 |c 05 |h 724-731 | ||